Treprostinil Sodium Market Report 2026

The treprostinil sodium market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to clinical effectiveness of prostacyclin therapy, expansion of pah diagnosis, hospital-based pah treatment, limited alternative therapies, improved survival outcomes.

The treprostinil sodium market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising pah prevalence, increasing long-term treatment adoption, expansion of inhalable and oral formulations, growing specialty clinic presence, rising awareness of pah. Major trends in the forecast period include rising use of prostacyclin analog therapies, increasing focus on pulmonary arterial hypertension, expansion of home-based pah treatment, growing adoption of multiple drug delivery routes, increased demand for long-term pah management.

The rising incidence of pulmonary diseases is expected to drive the expansion of the treprostinil sodium market in the coming years. Pulmonary diseases are disorders that affect the lungs and respiratory system, interfering with breathing and oxygen delivery. The growing prevalence of these conditions is attributed to factors such as air pollution, smoking, exposure to environmental toxins, and an aging population. Treprostinil sodium is a vasodilator that relaxes blood vessels in the lungs, lowers pressure, enhances breathing, and provides flexible treatment options for pulmonary diseases. For example, in June 2025, the Office for Health Improvement & Disparities, a UK government agency, reported that emergency hospital admissions for respiratory diseases in England increased by 7% between the financial years ending 2023 and 2024. Consequently, the rising cases of pulmonary diseases are fueling the growth of the treprostinil sodium market.

Major companies operating in the treprostinil sodium sector are concentrating on developing advanced therapies for pulmonary arterial hypertension, such as pulmonary vasodilator prostacyclin analog injections, to improve pulmonary hemodynamic regulation and symptom management in patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator prostacyclin analog injection is a biologically synthesized formulation of prostacyclin or its analog, administered intravenously or subcutaneously, that dilates pulmonary arteries, lowers pulmonary vascular resistance, and enhances blood flow in patients with PAH. For example, in April 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced the launch of Treprostinil Injection in the U.S., approved by the Food and Drug Administration, a U.S. government agency. Treprostinil injection is a therapeutic equivalent generic version of Remodulin (treprostinil) injection, belonging to a class of agents called prostacyclin mimetics, used for treating pulmonary arterial hypertension to reduce exercise-related symptoms. It is available in vials of 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, or 200 mg/20 mL.

In June 2023, Liquidia Corporation, a US-based pharmaceutical company, formed a partnership with Pharmosa Biopharm to develop inhaled, sustained-release treprostinil (L606) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The collaboration seeks to leverage Liquidia’s expertise in pulmonary hypertension and Pharmosa’s experience in inhaled liposomal formulations to improve treatment approaches in regions with limited access to inhaled treprostinil. Pharmosa Biopharm is a China-based manufacturer specializing in liposomal formulations of treprostinil.

Major companies operating in the treprostinil sodium market are United Therapeutics Corporation, Liquidia Corporation, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Mylan Laboratories Limited, Alembic Pharmaceuticals Ltd., Euroapi SA, Cipla Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, ChemWerth Inc., LGM Pharma, Simson Pharma Limited, YONSUNG Fine Chemicals Co. Ltd., Nuray Chemicals Private Limited, KPS Chemicals Pharmaceuticals, Farbe Firma Pvt. Ltd., Aurobindo Pharma Limited.

North America was the largest region in the treprostinil sodium market in 2025. The regions covered in the treprostinil sodium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the treprostinil sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of specialized APIs used in the production of treprostinil sodium for injectable and inhalable formulations. These impacts are most pronounced in Europe and Asia Pacific, where manufacturers rely on cross border sourcing for complex synthesis inputs. Rising tariff related expenses have influenced production costs, pricing strategies, and supply availability for pulmonary hypertension therapies. This has affected procurement planning across hospital and specialty pharmacy channels. Positively, tariffs are encouraging regional manufacturing investments, expanded local production capacity, and stronger long term supply resilience.

The treprostinil sodium market research report is one of a series of new reports that provides treprostinil sodium market statistics, including treprostinil sodium industry global market size, regional shares, competitors with a treprostinil sodium market share, detailed treprostinil sodium market segments, market trends and opportunities, and any further data you may need to thrive in the treprostinil sodium industry. This treprostinil sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Treprostinil sodium is a synthetic prostacyclin (PGI₂) analogue used to manage pulmonary arterial hypertension (PAH) by enhancing exercise tolerance and alleviating symptoms. It induces vasodilation, prevents platelet aggregation, and limits vascular remodeling, decreasing pulmonary pressure and improving blood circulation, which helps slow disease progression and enhances overall quality of life.

The primary forms of treprostinil sodium include injectable, inhalable, and oral. Treprostinil sodium injectable is utilized to manage pulmonary arterial hypertension (PAH) by enhancing exercise tolerance and alleviating symptoms through direct administration via syringe or needle. It finds use in a range of conditions, including pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and others, and is made available through multiple distribution channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies.

The treprostinil sodium market consists of sales of nasal spray formulation, buccal or lingual tablet, and nebulized solution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.